-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a research article published in Diabetes Care, an authoritative journal in the field of diabetes , used data from the National Health Insurance Service of Korea to evaluate the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors and retinal vein occlusion (RVO).
)
.
The researchers used national data from 2014 to 2017, based on a 1:1 propensity score match, and included 47369 new users of SGLT2 inhibitors and 47369 users of other glucose-lowering drugs (oGLD)
.
In the matched sample, the researchers used the Cox proportional hazards model to estimate the risk ratio (HR) and 95% CI for RVO
.
During the 2.
57-year follow-up period, the incidence of RVO in patients treated with SGLT2 inhibitors and oGLD was 2.
19 and 1.
79 per 1,000 people per year, respectively
.
Survival curve
In the subgroup analysis, the researchers observed a significant interaction between age and estimated glomerular filtration rate (eGFR) and SGLT2 inhibitors; RVO in patients over 60 years of age and eGFR<60mL/min/1.
73m2 HR is higher than other patients
.
Researchers found that SGLT2 inhibitors are associated with a significant increase in the risk of RVO
.
Elderly patients with chronic kidney disease and higher risk RVO original source: Sodium-Glucose cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among the Type 2 Patients With Diabetes: A Propensity Score-Matched Cohort Study In this message